By Steve Usdin
Contributing Editor

WASHINGTON - The FDA has agreed to make public the documents it provides to advisory committee members prior to panel meetings on post-marketing and non-approval issues, and is under pressure to extend this disclosure to all types of advisory committee meetings.

Although the agreement with the Public Citizen Health Research Group currently covers such post-approval issues as adverse events and product withdrawals, the agency still is negotiating over whether to release panel materials on new product reviews.